Table 3 Clinical endpoints
Zotarolimus-eluting stent (n = 350) | Sirolimus-eluting stent (n = 345) | Hazard ratio (95% confidence interval) | |
|---|---|---|---|
Major Adverse Cardiac Events | 46 (13.2%) | 9 (2.6%) | 5.29 (2.59-10.8) |
All cause death | 16 (4.6%) | 5 (1.5%) | 3.20 (1.17-8.72) |
Cardiac death | 7 (2.0%) | 1 (0.3%) | 6.97 (0.86-56.6) |
Myocardial infarction | 12 (3.4%) | 1 (0.3%) | 12.1 (1.57-92.8) |
Target vessel revascularization | 37 (10.6%) | 8 (2.3%) | 4.79 (2.23-10.3) |
Target lesion revascularization | 32 (9.2%) | 4 (1.2%) | 8.31 (2.94-23.5) |
In-stent restenosis | 24 (6.9%) | 3 (0.9%) | 8.23 (2.48-27.3) |
Definite stent thrombosis | 8 (2.3%) | 2 (0.6%) | 4.01 (0.85-18.9) |